Side effects control in the chemotherapy with everolimus: single-center experience
Journal Title: OncoReview - Year 2011, Vol 1, Issue 2
Abstract
BACKGROUND: Renal cell carcinoma (RCC, renal cell carcinoma) accounts for 80–85% of neoplasms arising from the kidney. Everolimus, one of the selective mTOR kinase inhibitors, was recently approved for the treatment of patients with RCC.Purpose: We aimed to evaluate the frequency of severe adverse events during everolimus chemotherapy in patients with renal cell carcinoma.Patients and methods : We analyzed data from medical records of patients with renal cell carcinoma treated with everolimus from January 2010 to February 2011. All patients had histologically confirmed renal cell carcinoma. Patients received everolimus in a single daily dose of 10 mg orally, in the 30-day cycles. The severity of adverse events were determined according to the scale of Common Toxicity Criteria for Adverse Events.Results : In our database we identified 51 patients with renal cell carcinoma who underwent everolimus therapy. Median age was 57 years (95% CI: 55–66). The most common hematological severe adverse events were: anemia in 10% of the patients, and lymphopenia in 4% of the patients. There were no other hematological toxicities in the 3rd or 4th degree. Hand-foot syndrome occurred in 2% of the patients in the intensity of the third degree. Among severe metabolic complications most commonly observed adverse events were: hyperglycemia in 6% of the patients, hypercholesterolemia in 6% and hypertriglyceridemia in 4%. Dose reduction was required in 4% of the patients due to nonbacterial pneumonia.Conclusions: In our study, everolimus was safe and well tolerated with few severe side effects.
Authors and Affiliations
Ludomir Bodnar, Rafał Stec, Marta Smoter
Keywords
Related Articles
- EP ID EP53097
- DOI -
- Views 238
- Downloads 0
Side effects control in the chemotherapy with everolimus: single-center experience
BACKGROUND: Renal cell carcinoma (RCC, renal cell carcinoma) accounts for 80–85% of neoplasms arising from the kidney. Everolimus, one of the selective mTOR kinase inhibitors, was recently approved for the treatment of p...
Tuberus sclerosis
Ongoing research developments in cardio-oncology
Limfohistiocytoza hemofagocytowa (HLH) indukowana przez chłoniaka – opis przypadku
Limfohistiocytoza hemofagocytowa (HLH) to rzadki (zwłaszcza u dorosłych) zespół objawów, w którym hiperzapalenie powoduje gorączkę, hepatosplenomegalię, pancytopenię i bez leczenia prowadzi do zgonu. Wśród wyników badań...
Compliance, adherence, persistence – przyczyny i konsekwencje niestosowania się pacjentów do zaleceń terapeutycznych
Nieprzestrzeganie zaleceń terapeutycznych znajduje się wśród najpoważniejszych problemów zdrowotnych ludzkości. Zostało uznane za jedną z najważniejszych przeszkód w osiąganiu korzyści z terapii opartej na aktualnej wied...